Meitav Investment House Ltd. Increases Stock Position in SPDR S&P Biotech ETF $XBI

Meitav Investment House Ltd. boosted its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 70.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 682,056 shares of the exchange traded fund’s stock after purchasing an additional 281,602 shares during the quarter. SPDR S&P Biotech ETF comprises 0.9% of Meitav Investment House Ltd.’s investment portfolio, making the stock its 27th largest holding. Meitav Investment House Ltd. owned 1.11% of SPDR S&P Biotech ETF worth $68,156,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Sequoia Financial Advisors LLC increased its stake in SPDR S&P Biotech ETF by 3.1% in the third quarter. Sequoia Financial Advisors LLC now owns 3,393 shares of the exchange traded fund’s stock valued at $340,000 after purchasing an additional 101 shares during the period. Fulcrum Capital LLC increased its position in SPDR S&P Biotech ETF by 2.7% in the 3rd quarter. Fulcrum Capital LLC now owns 56,433 shares of the exchange traded fund’s stock valued at $5,655,000 after acquiring an additional 1,473 shares during the period. OVERSEA CHINESE BANKING Corp Ltd purchased a new stake in SPDR S&P Biotech ETF during the 3rd quarter valued at approximately $4,803,000. BCS Private Wealth Management Inc. lifted its position in SPDR S&P Biotech ETF by 1.2% during the 3rd quarter. BCS Private Wealth Management Inc. now owns 36,546 shares of the exchange traded fund’s stock worth $3,662,000 after acquiring an additional 420 shares during the period. Finally, Wealth Advisory Solutions LLC grew its stake in shares of SPDR S&P Biotech ETF by 2.5% in the 3rd quarter. Wealth Advisory Solutions LLC now owns 10,507 shares of the exchange traded fund’s stock valued at $1,053,000 after purchasing an additional 257 shares during the last quarter.

SPDR S&P Biotech ETF Trading Down 0.1%

NYSEARCA:XBI opened at $124.18 on Friday. SPDR S&P Biotech ETF has a 12-month low of $66.66 and a 12-month high of $129.12. The stock’s 50 day simple moving average is $121.14 and its 200-day simple moving average is $104.39. The firm has a market cap of $8.22 billion, a P/E ratio of 11.47 and a beta of 0.93.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.